Dr. Joseph F. Merola

Dermatology | Rheumatology
5939 Harry Hines Blvd, 
Dallas, TX 
5939 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Merola is a Dermatologist and a Rheumatologist in Dallas, Texas. Dr. Merola is rated as an Experienced provider by MediFind in the treatment of Pompholyx Eczema. His top areas of expertise are Psoriasis, Cutaneous Lupus Erythematosus (CLE), Psoriatic Arthritis, and Arthritis.

His clinical research consists of co-authoring 393 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Rheumatology
Licenses
Dermatology in MA
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
5939 Harry Hines Blvd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Pro-Resolving Mediators in Acute Inflammation in Humans
Pro-Resolving Mediators in Acute Inflammation in Humans
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Other, Drug
Study Drug: Lovaza
Study Phase: Early Phase 1
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study
Enrollment Status: Terminated
Publish Date: October 04, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

393 Total Publications

Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis.
Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis.
Journal: JAMA dermatology
Published: August 20, 2025
Similar Doctors
Distinguished in Pompholyx Eczema
Dr. Ryan K. Pham
Dermatology
Distinguished in Pompholyx Eczema
Dr. Ryan K. Pham
Dermatology

Center For Dermatology

1100 Orchard Dr, Suite B, 
Arlington, TX 
 (16.4 miles away)
682-712-0100
Languages Spoken:
English, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Pham is a Dermatologist in Arlington, Texas. Dr. Pham is rated as a Distinguished provider by MediFind in the treatment of Pompholyx Eczema. His top areas of expertise are Rosacea, Warts, Epidermoid Cyst, and Actinic Keratosis. Dr. Pham is currently accepting new patients.

Distinguished in Pompholyx Eczema
Dr. Caitlin M. Farmer
Dermatology
Distinguished in Pompholyx Eczema
Dr. Caitlin M. Farmer
Dermatology

PDP Of Texas, PLLC

3200 Broadway Blvd, Ste 200, 
Garland, TX 
 (13.8 miles away)
469-800-6300
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Caitlin Farmer is a Dermatologist in Garland, Texas. Dr. Farmer has been practicing medicine for over 10 years and is rated as a Distinguished provider by MediFind in the treatment of Pompholyx Eczema. Her top areas of expertise are Plaque Psoriasis, Warts, Seborrheic Keratosis, and Malignant Hypertension.

Advanced in Pompholyx Eczema
Dr. Michael D. Meyer
Dermatology
Advanced in Pompholyx Eczema
Dr. Michael D. Meyer
Dermatology

PDP Of Texas, PLLC

1601 W Hebron Pkwy, Ste 220, 
Carrollton, TX 
 (15.1 miles away)
214-915-8515
Experience:
11+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Meyer is a Dermatologist in Carrollton, Texas. Dr. Meyer has been practicing medicine for over 11 years and is rated as a Distinguished provider by MediFind in the treatment of Pompholyx Eczema. His top areas of expertise are Plaque Psoriasis, Seborrheic Keratosis, Comedones, and Warts.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Merola's expertise for a condition
ConditionClose
View All 11 Elite Conditions
View All 22 Advanced Conditions
View All 125 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile